GlassScriptPhysician profile
Trisha A Stuckey
NPI 1467404418
$1,650.90
in general payments reported to CMS, 2019-2025
24 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $363 · 2022: $377 · 2023: $193 · 2024: $429 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.96 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $248.90 | 2024-2025 | Lumryz |
| Horizon Therapeutics Plc | $205.91 | 2022 | |
| Supernus Pharmaceuticals, INC. | $188.28 | 2022-2024 | Qelbree, Qelbree |
| Nevro Corp. | $167.91 | 2021 | |
| Medtronic, INC. | $137.10 | 2021-2024 | Intellis Adaptivestim |
| Stimwave Technologies Incorporated | $120.87 | 2021-2022 | |
| Indivior INC. | $80.56 | 2024-2025 | Sublocade |
| Avanir Pharmaceuticals, INC. | $57.70 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $57.60 | 2024 | Rexulti |
| Tris Pharma INC | $52.79 | 2023 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $38.03 | 2022-2023 | |
| Abbvie INC. | $35.54 | 2024-2025 | |
| Pfizer INC. | $30.91 | 2023 | |
| Orexo US, INC. | $28.09 | 2023 | Zubsolv |
| Merck Sharp & Dohme LLC | $28.09 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $23.35 | 2022 | |
| Si-Bone, INC. | $23.17 | 2021 | |
| Alkermes, INC. | $23.08 | 2023 | Vivitrol |
| Valinor Pharma, LLC | $21.13 | 2025 | Movantik |
| Upsher-Smith Laboratories LLC | $18.57 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.86 | 2022 | |
| Lilly USA, LLC | $17.48 | 2021 | |
| Boston Scientific Corporation | $14.37 | 2021 | |
| Eisai INC. | $13.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Stuckey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.